Provided by Tiger Trade Technology Pte. Ltd.

Adagene

3.31
+0.03501.07%
Volume:153.27K
Turnover:506.42K
Market Cap:221.91M
PE:-8.76
High:3.55
Open:3.53
Low:3.21
Close:3.27
52wk High:4.85
52wk Low:1.30
Shares:67.14M
Float Shares:58.88M
Volume Ratio:1.34
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3773
EPS(LYR):-0.3750
ROE:-28.50%
ROA:-13.95%
PB:2.48
PE(LYR):-8.81

Loading ...

Adagene Inc. Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Adagene CEO Peter Luo Buys 23,245 ADS Worth $84,763.97

Reuters
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 14

Adagene Posts Investor Presentation Highlighting Adg126 Masked Anti-ctla-4 Program in MSS Colorectal Cancer

Reuters
·
Jul 07

Adagene joins Stifel Annual Virtual Oncology Event for fireside chat, investor meetings

Reuters
·
May 12

Adagene to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
May 12

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)

TIPRANKS
·
May 03

Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints

TIPRANKS
·
Apr 27

Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers

TIPRANKS
·
Apr 18

Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR

TIPRANKS
·
Apr 18

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

GlobeNewswire
·
Apr 18

Adagene adds Third Arc Bio CEO Peter Lebowitz to advisory board

Reuters
·
Apr 14

Press Release: Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Dow Jones
·
Apr 14

New Adagene Immuno‑Oncology Tie‑Up Could Be A Game Changer For Incyte (INCY)

Simply Wall St.
·
Apr 13

Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program

TIPRANKS
·
Apr 06

Adagene Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 06

Adagene price target raised to $10 from $9 at Guggenheim

TIPRANKS
·
Apr 06

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live
·
Apr 02

Adagene Drug Shows Stronger Tumor Response at Higher Dose in Early Cancer Trial

Dow Jones
·
Apr 02

Adagene 18.666M share Spot Secondary priced at $3.75

TIPRANKS
·
Apr 02